Expansion of monocytic myeloid-derived suppressor cells in endometriosis patients: A pilot study

Haiwen Chen, Shuang Qin, Aihua Lei, Xing Li, Qi Gao, Jingyin Dong, Qing Xiao, Jie Zhou
International immunopharmacology · 2017 · vol. 47 , pp. 150–158 · doi:10.1016/j.intimp.2017.03.026 · PMID:28407569 · W2605844998
article OA: closed CC0 ⤵ 17 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This pilot study investigated and found an expansion of monocytic myeloid-derived suppressor cells in patients diagnosed with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Endometriosis Monocytes Myeloid-Derived Suppressor Cells T-Lymphocytes Adolescent Adult CD11b Antigen CD11b Antigen Cell Proliferation Cells, Cultured Coculture Techniques Disease Progression Endometriosis Female HLA-DR Antigens HLA-DR Antigens Humans Immune Tolerance Lipopolysaccharide Receptors Lipopolysaccharide Receptors

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (36)

Cited by (17)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:20:31.759405+00:00
License: CC0 · commercial use OK